Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Read More »
Crudo o tostado, con o sin cáscara, en crema o como base de salsas, sin olvidar el glamuroso chocolate “al estilo Dubai”. El pistacho, que antes se consideraba casi un aperitivo de lujo, se ha convertido en el fruto seco de moda en muchos países y está cada vez m&aacut …
Fabrican una batería con cáscaras de pistacho sin emplear litio ni metales críticos Read More »
Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. The answer blew past expectations by 86%.
Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales Read More »
Viridian Therapeutics’ elegrobart normalized the degree of eye protrusion and improved double vision in a Phase 3 study. The company plans to file for approval in the first quarter of 2027.
Viridian turns green again as new Phase 3 data vindicate thyroid eye disease drug Read More »
For $300 million upfront, Bayer is purchasing Perfuse Therapeutics to advance an eye implant for glaucoma and diabetic retinopathy, marking the company’s first pharma acquisition since 2021.
Bayer ends multi-year M&A drought with up to $2.45B Perfuse buy Read More »
Facing increasing pressure from both industry and the White House, FDA Commissioner Marty Makary said the strong bad press against him is “corporate spin” and that the agency has “followed the science.”
Makary defends Replimune melanoma rejection again as FDA tensions build Read More »
Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative colitis.
J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails Read More »
First quarter earnings continue to arrive, with analysts demanding more from cautious Pfizer and Eli Lilly expecting more revenue; the FDA taps Katherine Szarama as Vinay Prasad’s controversial FDA tenure ends; oncology veterans miss Richard Pazdur at the agency’s first adcomm in nine months; and QurAlis and Corcept Therapeutics spark renewed hope in ALS.
Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening Read More »
La trayectoria de François Auguste Victor Grignard (1871-1935) es, ante todo, una lección de humildad, perseverancia y pragmatismo francés. Sin su descubrimiento, la medicina moderna, la industria del perfume y la síntesis de plásticos tal como los conocemos simple …
Victor Grignard: El Nobel que encontró en el magnesio el eslabón perdido de la Química Read More »
En el mundo de la ciencia computacional, existen hitos que no se miden por la potencia de los procesadores, sino por la elegancia de su lógica. Si 1969 fue el año del Internet, 2008 fue el año de la arquitectura de la confianza. Con la publicación del whitepaper de Bitcoi …
